Transdermal therapeutic system for administration of partial dopamine-d2 agonists
OwnerThorsten Selzerinventor
Life of this patent
Estimating the term…
Abstract
A transdermal therapeutic system (TTS) for administering at least one partial dopamine D2 agonist, comprising an active substance-impermeable backing layer, an active substance reservoir and a detachable protective layer, where the active substance reservoir is pressure-sensitive adhesive or the TTS is provided with at least one pressure-sensitive adhesive layer, and where the active substance reservoir is configured as a matrix system or as a membrane system, is characterized in that the active substance reservoir contains at least one active substance from the group of partial dopamine D2 agonists.
Claims20
Transdermal therapeutic system (TTS) for administering at least one partial dopamine D2 agonist, having an active substance-impermeable backing layer, an active substance reservoir and a detachable backing layer, where the active substance reservoir is pressure-sensitive adhesive or the TTS has at least one pressure-sensitive adhesive layer, and where the active substance reservoir is configured as a matrix system or as a membrane system, characterized in that the active substance reservoir contains at least one active substance from the group of the partial dopamine D2 agonists.
TTS according to any one of the preceding claims, characterized in that the active substance reservoir contains a fibre material, a woven fabric or a nonwoven, to which the active substance is adsorbed.
TTS according to any one of the preceding claims, characterized in that it additionally has an active substance-permeable membrane which modifies or controls the rate of active substance release.
TTS according to any one of the preceding claims, characterized in that aripiprazole is contained in a concentration in the range of from 0.1 to 50%-wt., preferably from 1 to 10%-wt, in each case relative to the total mass of the active substance reservoir.
TTS according to any one of the preceding claims, characterized in that aripiprazole is present in the active substance reservoir in dissolved state.
TTS according to any one of the preceding claims, characterized in that the active substance reservoir contains at least one solubilizer, preferably in an amount of from 1 to 50%-wt., with particular preference from 5 to 35%-wt., in each case relative to the total weight of the active substance reservoir.
TTS according to any one of the preceding claims, characterized in that the active substance reservoir contains at least one permeation-enhancing substance, preferably in an amount of from 0.1 to 25%-wt, with particular preference from 1 to 10%-wt, in each case relative to the total weight of the active substance reservoir.
TTS according to any one of the preceding claims, characterized in that it additionally contains at least one active substance selected from the group comprising phenothiazines and its analogues, butyrophenones and diphenylbutyl piperidines.
The use of aripiprazole for production of a transdermal therapeutic system comprising an active substance-impermeable backing layer, an active substance reservoir and a detachable protective layer, where the active substance reservoir is pressure-sensitive adhesive or the TTS has at least one pressure-sensitive adhesive layer.
Method of drug treatment of acute and/or chronic symptoms of schizophrenic psychoses, characterized in that a TTS containing aripiprazole is applied to the skin of a patient suffering from a schizophrenic psychosis.
Method for administering aripiprazole via the skin to a person in need of a partial dopamine D2 agonist, characterized in that
- a) a transdermal therapeutic system (TTS), comprising an active substance-impermeable backing layer, an active substance reservoir containing aripiprazole, a pressure-sensitive adhesive layer, possibly an active substance-permeable membrane, and a detachable protective layer, is freed from the detachable protective layer,
- b) the TTS is applied with its pressure-sensitive adhesive layer to the intact skin of the patient,
- c) the aripiprazole contained in the active substance reservoir is released from the active substance reservoir through the pressure-sensitive adhesive layer and possibly the active substance-permeable membrane over a period of at least 8 hours to the patient's skin, and
- d) the TTS is removed from the patient's skin after a period of 8 hours, maximally, however, after a period of 3 days, from the patient's skin.
Dependencies are inferred from the claim text.